Literature DB >> 9694850

Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.

U Vijapurkar1, K Cheng, J G Koland.   

Abstract

The ErbB2 and ErbB3 proteins together constitute a functional coreceptor for heregulin (neuregulin). Heregulin stimulates the phosphorylation of both coreceptor constituents and initiates a variety of other signaling events, which include phosphorylation of the Shc protein. The role of Shc in heregulin-stimulated signal transduction through the ErbB2.ErbB3 coreceptor was investigated here. Heregulin was found to promote ErbB3/Shc association in NIH-3T3 cells expressing endogenous ErbB2 and recombinant ErbB3. A mutant ErbB3 protein was generated in which Tyr-1325 in a consensus Shc phosphotyrosine-binding domain recognition site was mutated to Phe (ErbB3-Y/F). This mutation abolished the association of Shc with ErbB3 and blocked the activation of mitogen-activated protein kinase by heregulin. Whereas heregulin induced mitogenesis in NIH-3T3 cells transfected with wild-type ErbB3 cDNA, this mitogenic response was markedly attenuated in NIH-3T3 cells transfected with the ErbB3-Y/F cDNA. These results showed a specific interaction of Shc with the ErbB3 receptor protein and demonstrated the importance of this interaction in the activation of mitogenic responses by the ErbB2. ErbB3 heregulin coreceptor complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694850     DOI: 10.1074/jbc.273.33.20996

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.

Authors:  Josie Ursini-Siegel; Sean Cory; Dongmei Zuo; William R Hardy; Elton Rexhepaj; Sonya Lam; Babette Schade; Karin Jirstrom; Eva Bjur; Ciriaco A Piccirillo; David Denardo; Lisa M Coussens; Donal J Brennan; William M Gallagher; Morag Park; Tony Pawson; Michael Hallett; William J Muller
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

3.  Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays.

Authors:  Matthew J Smith; W Rod Hardy; James M Murphy; Nina Jones; Tony Pawson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

4.  PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.

Authors:  Howard M Stern; Humphrey Gardner; Tomasz Burzykowski; Wafaa Elatre; Carol O'Brien; Mark R Lackner; Gary A Pestano; Angela Santiago; Ivonne Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Paolo Nuciforo; Valerie Bee; John Mackey; Dennis J Slamon; Michael F Press
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

5.  Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Authors:  Naoki Kanomata; Junichi Kurebayashi; Takuya Moriya
Journal:  Med Mol Morphol       Date:  2018-10-13       Impact factor: 2.309

6.  Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Authors:  Liqun Chen; Salma Siddiqui; Swagata Bose; Benjamin Mooso; Alfredo Asuncion; Roble G Bedolla; Ruth Vinall; Clifford G Tepper; Regina Gandour-Edwards; Xubao Shi; Xiao-Hua Lu; Javed Siddiqui; Arul M Chinnaiyan; Rohit Mehra; Ralph W Devere White; Kermit L Carraway; Paramita M Ghosh
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

7.  Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells.

Authors:  Han Jin Cho; Woo Kyoung Kim; Jae In Jung; Eun Ji Kim; Soon Sung Lim; Dae Young Kwon; Jung Han Yoon Park
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

Review 8.  The biology of human epidermal growth factor receptor 2.

Authors:  S Sundaresan; E Penuel; M X Sliwkowski
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

Review 10.  Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.

Authors:  Neha Sami; Vijay Kumar; Asimul Islam; Sher Ali; Faizan Ahmad; Imtaiyaz Hassan
Journal:  Mol Neurobiol       Date:  2016-08-20       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.